Prognostic study of the risk of progression or relapse
| Characteristics . | Univariate analysis . | Multivariate analysis . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Categories exposed/reference . | RR . | (95% CI) . | P . | RR . | Final model* (95% CI) . | P . | RR . | Additional variables† (95% CI) . | P . | |
| Sex | male / female | 0.95 | (0.58-1.6) | .85 | — | — | — | — | — | — |
| Age | ≥10 years/<10 years | 0.81 | (0.50-1.3) | .41 | — | — | — | — | — | — |
| Immunophenotype | null / T | 1.14 | (0.61-2.1) | .69 | — | — | — | — | — | — |
| ALK positivity | yes / no | 1.24 | (0.38-4.0) | .72 | — | — | — | — | — | — |
| B symptoms | yes / no | 2.3 | (1.4-4.0) | .002 | — | — | — | 1.7 | (0.96-3.0) | .07 |
| Lymph nodes | yes / no | 2.2 | (0.7-7.1) | .13 | — | — | — | — | — | — |
| Lymph nodes, mediastinal involvement | yes / no | 2.6 | (1.6-4.3) | <.001 | 2.1 | (1.2-3.5) | .006 | — | — | — |
| Skin lesions | yes / no | 2.0 | (1.2-2.3) | .008 | 1.9 | (1.1-3.2) | .015 | — | — | — |
| Bone lesions | yes / no | 0.38 | (0.13-1.0) | .04 | — | — | — | 0.46 | (0.16-1.3) | .09 |
| Soft tissue | yes / no | 0.94 | (0.45-2.0) | .87 | — | — | — | — | — | — |
| Marrow involvement | yes / no | 1.4 | (0.63-3.1) | .43 | — | — | — | — | — | — |
| Visceral involvement | yes / no | 2.1 | (1.3-3.4) | .004 | — | — | — | — | — | — |
| Spleen involvement | yes / no | 2.4 | (1.4-4.0) | .003 | — | — | — | — | — | — |
| Liver involvement | yes / no | 2.2 | (1.3-3.9) | .007 | 2.1‡ | (1.3-3.6) | .004 | — | — | — |
| Lung involvement | yes / no | 3.0 | (1.7-5.3) | <.005 | — | — | — | — | — | — |
| Other visceral involvement | yes / no | 1.5 | (0.8-2.6) | .18 | — | — | — | 1.2 | (0.58-1.9) | .85 |
| St Jude | stage 3-4 / 1-2 | 2.6 | (1.3-5.2) | .003 | — | — | — | 1.3 | (0.55-2.9) | .58 |
| Ann Arbor | stage 3-4 / 1-2 | 2.0 | (1.0-3.8) | .03 | — | — | — | 0.91 | (0.41-2.0) | .81 |
| LDH | ≥2×ULN/<2×ULN | 2.7 | (1.3-5.7) | .01 | — | — | — | 2.0 | (0.98-4.3) | .07 |
| Characteristics . | Univariate analysis . | Multivariate analysis . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Categories exposed/reference . | RR . | (95% CI) . | P . | RR . | Final model* (95% CI) . | P . | RR . | Additional variables† (95% CI) . | P . | |
| Sex | male / female | 0.95 | (0.58-1.6) | .85 | — | — | — | — | — | — |
| Age | ≥10 years/<10 years | 0.81 | (0.50-1.3) | .41 | — | — | — | — | — | — |
| Immunophenotype | null / T | 1.14 | (0.61-2.1) | .69 | — | — | — | — | — | — |
| ALK positivity | yes / no | 1.24 | (0.38-4.0) | .72 | — | — | — | — | — | — |
| B symptoms | yes / no | 2.3 | (1.4-4.0) | .002 | — | — | — | 1.7 | (0.96-3.0) | .07 |
| Lymph nodes | yes / no | 2.2 | (0.7-7.1) | .13 | — | — | — | — | — | — |
| Lymph nodes, mediastinal involvement | yes / no | 2.6 | (1.6-4.3) | <.001 | 2.1 | (1.2-3.5) | .006 | — | — | — |
| Skin lesions | yes / no | 2.0 | (1.2-2.3) | .008 | 1.9 | (1.1-3.2) | .015 | — | — | — |
| Bone lesions | yes / no | 0.38 | (0.13-1.0) | .04 | — | — | — | 0.46 | (0.16-1.3) | .09 |
| Soft tissue | yes / no | 0.94 | (0.45-2.0) | .87 | — | — | — | — | — | — |
| Marrow involvement | yes / no | 1.4 | (0.63-3.1) | .43 | — | — | — | — | — | — |
| Visceral involvement | yes / no | 2.1 | (1.3-3.4) | .004 | — | — | — | — | — | — |
| Spleen involvement | yes / no | 2.4 | (1.4-4.0) | .003 | — | — | — | — | — | — |
| Liver involvement | yes / no | 2.2 | (1.3-3.9) | .007 | 2.1‡ | (1.3-3.6) | .004 | — | — | — |
| Lung involvement | yes / no | 3.0 | (1.7-5.3) | <.005 | — | — | — | — | — | — |
| Other visceral involvement | yes / no | 1.5 | (0.8-2.6) | .18 | — | — | — | 1.2 | (0.58-1.9) | .85 |
| St Jude | stage 3-4 / 1-2 | 2.6 | (1.3-5.2) | .003 | — | — | — | 1.3 | (0.55-2.9) | .58 |
| Ann Arbor | stage 3-4 / 1-2 | 2.0 | (1.0-3.8) | .03 | — | — | — | 0.91 | (0.41-2.0) | .81 |
| LDH | ≥2×ULN/<2×ULN | 2.7 | (1.3-5.7) | .01 | — | — | — | 2.0 | (0.98-4.3) | .07 |
RR refers to ratio of risk of progression or relapse in exposed/reference category.
— indicates not done.
Includes the 3 variables in the table, stratified on study group.
Test of the additional value of each characteristic given the final model.
Spleen, liver, or lung involvement versus no involvement of any of these organs.